GlassScriptPhysician profile
Sarah Riggio
NPI 1720575046
$800.78
in general payments reported to CMS, 2019-2025
14 companies · $59.34 in 2025
The $59.34 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.61 · 2022: $66.32 · 2023: $351 · 2024: $286 · 2025: $59.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.82 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $151.09 | 2023-2024 | Injectafer |
| Abbott Laboratories | $133.03 | 2024 | Cardiomems |
| Janssen Biotech, INC. | $73.03 | 2024-2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $61.15 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.23 | 2022-2023 | Jardiance |
| Pfizer INC. | $53.66 | 2022-2023 | |
| Scpharmaceuticals INC. | $50.03 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $44.94 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $33.68 | 2021-2022 | |
| One Lambda, INC. | $33.63 | 2024 | |
| Kci USA, INC. | $31.34 | 2023 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Novartis Pharmaceuticals Corporation | $27.72 | 2024 | |
| Solventum Corporation | $25.95 | 2024 | Activ.A.C. |
| Astrazeneca Pharmaceuticals LP | $23.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Riggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.